11/26
11:10 am
prld
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Medium
Report
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
11/20
10:00 am
prld
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
11/19
10:40 am
prld
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Low
Report
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
11/12
08:21 am
prld
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
07:01 am
prld
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/11
11:24 pm
prld
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
High
Report
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
11/3
09:01 am
prld
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
High
Report
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
10/18
01:31 am
prld
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
Medium
Report
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
10/17
07:30 am
prld
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Medium
Report
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
9/23
08:07 am
prld
Prelude Therapeutics (NASDAQ:PRLD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
High
Report
Prelude Therapeutics (NASDAQ:PRLD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.